Sionna Therapeutics, Inc.

Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.

SION | US

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 21 HICKORY DRIVE, SUITE 500, 2451 WALTHAM
Website:: https://www.sionnatx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for cystic fibrosis (CF). The company's mission is to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its novel approach centers on stabilizing the protein's nucleotide-binding domain 1 (NBD1), which directly targets the defect caused by F508del, the most common CF-causing mutation. Sionna is advancing a pipeline of proprietary small molecule NBD1 stabilizers, such as SION-719, and a portfolio of complementary CFTR modulators designed to work synergistically. The ultimate goal is to restore CFTR function to near-normal levels, revolutionizing the treatment paradigm for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sionna Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sionna Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Sionna Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Armata Pharmaceuticals, Inc. Developing bacteriophage therapeutics for antibiotic-resistant infections.	United States of America	ARMP
AroCell AB Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.	Sweden	AROC
ArriVent BioPharma, Inc. A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.	United States of America	AVBP
ARROWHEAD PHARMACEUTICALS, INC. Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.	United States of America	ARWR
ARS Pharmaceuticals, Inc. Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.	United States of America	SPRY
ARTELO BIOSCIENCES, INC. Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.	United States of America	ARTL
Artiva Biotherapeutics, Inc. Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.	United States of America	ARTV
Ascelia Pharma Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.	Sweden	ACE
Ascendis Pharma A/S Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.	United States of America	ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.	United States of America	AAPG